Developer docs
API playgroundTry for free, no card

Search company profiles

Chemcrux Enterprises

Full company profile

uuid000auif

Namestring
Chemcrux Enterprises
Legal namestring
Chemcrux Enterprises Limited
Websiteurl
chemcrux.com
Company typeenum
Public
Founded yearint
1983
Descriptiontext

Chemcrux Enterprises Limited is an India-based, publicly listed (BSE: CHEMCRUX, 'B' group) chemical production company headquartered in Vadodara, Gujarat, that manufactures intermediates and chemicals used in the production of bulk drugs. Founded in 1983, the company operates with a headcount of 51–100 employees and reports under SEBI (LODR) Regulations 2015 disclosure obligations. Its core business is the manufacturing and sale of chemical products, with the most recent disclosed quarterly result (Q4 FY25-26) showing ₹24.28 crore in revenue, ₹4.19 crore in operating profit, and ₹1.85 crore in net profit.

The company operates through Kalichem Private Limited, a wholly-owned subsidiary that runs a chemical manufacturing facility in Vadodara, Gujarat. Kalichem has filed a CTE-Amendment application with the Gujarat Pollution Control Board to add inorganic chemicals manufacturing at this site, signaling a strategic diversification beyond the company's existing intermediates and bulk-drug chemical product base into the inorganic chemicals vertical. Customer-facing information is limited: the only disclosed customer segment is the industrial chemicals sector, with no named logos, customer counts, or pricing structure available publicly. Founder Sanjay Marathe is identified as the owner.

Chemcrux monetizes primarily through one-time sales of manufactured chemical products rather than subscription or licensing models. Revenue is generated on a transactional manufacturing-and-sale basis, with no publicly disclosed pricing tiers, contract structures, or distribution channel detail. Stock liquidity is thin (45,219 shares traded on April 17, 2026 versus a one-month average daily volume of 15,197 shares), and the share price declined 11.98% to ₹87.3 on the same date, consistent with a micro-cap public listing.

Short descriptiontext

Chemcrux Enterprises is a publicly listed Indian chemical manufacturer in Vadodara producing intermediates and chemicals for bulk drug production, operating through subsidiary Kalichem Private Limited and serving the industrial chemicals sector.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersVadodara, India
HQ citystring
Vadodara
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
bulk drug intermediates, chemical manufacturing, pharmaceutical intermediates, inorganic chemicals, specialty chemicals
Industry2 codes
1Electronic & High-Purity Specialty Chemicals
CodeIMAEABADPrimaryYes
2Bulk Industrial Solvents
CodeIMAEAAAEPrimaryNo
NAICS code2 codes
  • Other Basic Organic Chemical Manufacturing32519
  • Chemical Manufacturing325
SIC code2 codes
  • Medicinal Chemicals & Botanical Products2833
  • Industrial Organic Chemicals2860
Product category
Specialty Chemicals (Pharmaceutical Intermediates)
No data
Revenue model1 record
1Chemicals Manufacturing and Sales
TypeOne Time License
Description

Revenue generated from manufacturing and sale of chemical products. The company reported Q4 FY25-26 revenue of ₹24.28 crore with significant year-on-year growth of 54.45%.

business-standard.com
Cost components6 values
Operations, Supply Chain, Personnel, Infrastructure, Technology or R&D, Marketing or Sales
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Chemcrux Enterprises manufactures and supplies chemical intermediates and chemicals used by other companies to produce bulk drugs (active pharmaceutical ingredients). Through its wholly-owned subsidiary Kalichem Private Limited, the company is diversifying into inorganic chemicals manufacturing at its Vadodara, Gujarat facility, pending regulatory approval from the Gujarat Pollution Control Board.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Revenue grew 54.45% YoY to ₹24.28 crore in Q4 FY25-26
+2 more records
Product and service1 record
1Chemical intermediates for bulk drug manufacturing
CategoryPharmaceutical intermediates / bulk drug chemicals
Description

Chemical intermediates and chemicals supplied to pharmaceutical manufacturers for use in the production of bulk drugs (active pharmaceutical ingredients). Sold to industrial buyers in the Indian pharmaceutical value chain.

Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move3 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight3 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Indian specialty chemicals manufacturer producing intermediates and fine chemicals serving pharmaceutical, agrochemical, and polymer customers. Most directly comparable to Chemcrux given shared focus on chemical intermediates and pharmaceutical end-markets.

TypeDirect peer
Description

Diversified Indian chemical manufacturer producing intermediates and specialty chemicals for pharmaceutical and industrial applications. Comparable through its intermediates portfolio serving bulk drug and specialty chemical customers.

TypeDirect peer
Description

Indian specialty fluorochemicals manufacturer serving pharmaceutical and agrochemical customers with high-purity intermediates. Comparable through its specialty chemical intermediates serving pharmaceutical manufacturers.

TypeDirect peer
Description

Indian specialty organic chemicals manufacturer producing intermediates for pharmaceutical and industrial applications. Comparable through its focus on organic chemical intermediates and pharmaceutical end-markets.

TypeDirect peer
Description

Indian specialty chemical manufacturer focused on pharmaceutical and agrochemical intermediates. Comparable given its pharmaceutical intermediates focus and similar Indian small-cap listed status.

TypeDirect peer
Description

Indian specialty chemicals manufacturer producing intermediates and performance chemicals for pharma and food applications. Comparable given similar intermediate-focused business model and Indian listed status.

TypeDirect peer
Description

Indian specialty chemicals manufacturer of oleochemical-based specialty additives and intermediates. Comparable given similar specialty intermediates business and Indian listed small-cap profile.

TypeBroad incumbent
Description

Large Indian diversified chemicals conglomerate with significant specialty intermediates and pharma intermediates business. Comparable in product categories but operates at substantially larger scale across multiple chemical verticals.

TypeBroad incumbent
Description

Large Indian agrochemical and specialty chemicals manufacturer with custom synthesis and intermediates capabilities. Comparable given its intermediates and custom manufacturing operations serving global customers.

TypeEmerging player
Description

Indian specialty chemicals manufacturer focused on custom synthesis and intermediates for pharmaceutical and agrochemical customers. Comparable given similar intermediates-focused model and Indian listed status, though serving different customer mix.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Chemcrux Enterprises

Specialty Chemicals (Pharmaceutical Intermediates)chemcrux.com

Chemcrux Enterprises is a publicly listed Indian chemical manufacturer in Vadodara producing intermediates and chemicals for bulk drug production, operating through subsidiary Kalichem Private Limited and serving the industrial chemicals sector.

What Chemcrux Enterprises does

Chemcrux Enterprises Limited is an India-based, publicly listed (BSE: CHEMCRUX, 'B' group) chemical production company headquartered in Vadodara, Gujarat, that manufactures intermediates and chemicals used in the production of bulk drugs. Founded in 1983, the company operates with a headcount of 51–100 employees and reports under SEBI (LODR) Regulations 2015 disclosure obligations. Its core business is the manufacturing and sale of chemical products, with the most recent disclosed quarterly result (Q4 FY25-26) showing ₹24.28 crore in revenue, ₹4.19 crore in operating profit, and ₹1.85 crore in net profit.

The company operates through Kalichem Private Limited, a wholly-owned subsidiary that runs a chemical manufacturing facility in Vadodara, Gujarat. Kalichem has filed a CTE-Amendment application with the Gujarat Pollution Control Board to add inorganic chemicals manufacturing at this site, signaling a strategic diversification beyond the company's existing intermediates and bulk-drug chemical product base into the inorganic chemicals vertical. Customer-facing information is limited: the only disclosed customer segment is the industrial chemicals sector, with no named logos, customer counts, or pricing structure available publicly. Founder Sanjay Marathe is identified as the owner.

Chemcrux monetizes primarily through one-time sales of manufactured chemical products rather than subscription or licensing models. Revenue is generated on a transactional manufacturing-and-sale basis, with no publicly disclosed pricing tiers, contract structures, or distribution channel detail. Stock liquidity is thin (45,219 shares traded on April 17, 2026 versus a one-month average daily volume of 15,197 shares), and the share price declined 11.98% to ₹87.3 on the same date, consistent with a micro-cap public listing.

Chemcrux Enterprises firmographics

Firmographics
Name
Chemcrux Enterprises
Legal name
Chemcrux Enterprises Limited
Website
https://chemcrux.com
Company type
Public
Founded year
1983
Operating status
Operating
Headcount range
51–100 employees
Short description
Chemcrux Enterprises is a publicly listed Indian chemical manufacturer in Vadodara producing intermediates and chemicals for bulk drug production, operating through subsidiary Kalichem Private Limited and serving the industrial chemicals sector.
Ownership category
akta.pro rank

Chemcrux Enterprises industry classification

Industry
Product category
Specialty Chemicals (Pharmaceutical Intermediates)
NAICS
Other Basic Organic Chemical Manufacturing (32519), Chemical Manufacturing (325)
SIC
Medicinal Chemicals & Botanical Products (2833), Industrial Organic Chemicals (2860)
akta.pro primary industry
Electronic & High-Purity Specialty Chemicals (IMAEABAD)
akta.pro secondary industry
Bulk Industrial Solvents (IMAEAAAE)

Keywords

  • Bulk drug intermediates
  • Chemical manufacturing
  • Pharmaceutical intermediates
  • Inorganic chemicals
  • Specialty chemicals

Where Chemcrux Enterprises is headquartered

Location

Headquarters

HQ city
Vadodara
HQ country
India
HQ region
Asia

Offices1 record

Markets served

Chemcrux Enterprises business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Supply Chain, Personnel, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Chemicals Manufacturing and Sales: Revenue generated from manufacturing and sale of chemical products. The company reported Q4 FY25-26 revenue of ₹24.28 crore with significant year-on-year growth of 54.45%.

Chemcrux Enterprises product offering

Product offering

Core offering

Chemcrux Enterprises manufactures and supplies chemical intermediates and chemicals used by other companies to produce bulk drugs (active pharmaceutical ingredients). Through its wholly-owned subsidiary Kalichem Private Limited, the company is diversifying into inorganic chemicals manufacturing at its Vadodara, Gujarat facility, pending regulatory approval from the Gujarat Pollution Control Board.

Differentiator

Problem solved

Functional benefit

Products and services

  • Chemical intermediates for bulk drug manufacturing Chemical intermediates and chemicals supplied to pharmaceutical manufacturers for use in the production of bulk drugs (active pharmaceutical ingredients). Sold to industrial buyers in the Indian pharmaceutical value chain.

Quantifiable outcome

  • Revenue grew 54.45% YoY to ₹24.28 crore in Q4 FY25-26
  • +2 more outcomes

Companies that use Chemcrux Enterprises

Customer profile

Segments1 record

Ideal customer profiles2 records

Chemcrux Enterprises technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Chemcrux Enterprises partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves3 records

Expansion highlights3 records

Chemcrux Enterprises competitors and assessment

Company assessment

Direct peers

  • Aarti Industries: Indian specialty chemicals manufacturer producing intermediates and fine chemicals serving pharmaceutical, agrochemical, and polymer customers. Most directly comparable to Chemcrux given shared focus on chemical intermediates and pharmaceutical end-markets.
  • Atul Limited: Diversified Indian chemical manufacturer producing intermediates and specialty chemicals for pharmaceutical and industrial applications. Comparable through its intermediates portfolio serving bulk drug and specialty chemical customers.
  • Navin Fluorine International: Indian specialty fluorochemicals manufacturer serving pharmaceutical and agrochemical customers with high-purity intermediates. Comparable through its specialty chemical intermediates serving pharmaceutical manufacturers.
  • Vinati Organics: Indian specialty organic chemicals manufacturer producing intermediates for pharmaceutical and industrial applications. Comparable through its focus on organic chemical intermediates and pharmaceutical end-markets.
  • Tatva Chintan Pharma Chem: Indian specialty chemical manufacturer focused on pharmaceutical and agrochemical intermediates. Comparable given its pharmaceutical intermediates focus and similar Indian small-cap listed status.
  • Camlin Fine Sciences: Indian specialty chemicals manufacturer producing intermediates and performance chemicals for pharma and food applications. Comparable given similar intermediate-focused business model and Indian listed status.
  • Fine Organic Industries: Indian specialty chemicals manufacturer of oleochemical-based specialty additives and intermediates. Comparable given similar specialty intermediates business and Indian listed small-cap profile.

Broad incumbents

  • SRF Limited: Large Indian diversified chemicals conglomerate with significant specialty intermediates and pharma intermediates business. Comparable in product categories but operates at substantially larger scale across multiple chemical verticals.
  • PI Industries: Large Indian agrochemical and specialty chemicals manufacturer with custom synthesis and intermediates capabilities. Comparable given its intermediates and custom manufacturing operations serving global customers.

Emerging players

  • Anupam Rasayan: Indian specialty chemicals manufacturer focused on custom synthesis and intermediates for pharmaceutical and agrochemical customers. Comparable given similar intermediates-focused model and Indian listed status, though serving different customer mix.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat3 records

Key risks6 records

Key highlights5 records

Customer concentration

Chemcrux Enterprises financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Chemcrux Enterprises leadership team

Management profile

Number of profiles

Profiles1 record

Chemcrux Enterprises subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

Chemcrux Enterprises funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Chemcrux Enterprises M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Chemcrux Enterprises

What does Chemcrux Enterprises do?

Chemcrux Enterprises manufactures and supplies chemical intermediates and chemicals used by other companies to produce bulk drugs (active pharmaceutical ingredients). Through its wholly-owned subsidiary Kalichem Private Limited, the company is diversifying into inorganic chemicals manufacturing at its Vadodara, Gujarat facility, pending regulatory approval from the Gujarat Pollution Control Board.

Is Chemcrux Enterprises a public or private company?

Chemcrux Enterprises is a public company. It is classified as public and is currently operating.

When was Chemcrux Enterprises founded?

Chemcrux Enterprises was founded in 1983. It employs 51 to 100 people.

Where is Chemcrux Enterprises based?

Chemcrux Enterprises is headquartered in Vadodara, India, in the Asia region.

How does Chemcrux Enterprises make money?

One revenue line is on record: chemicals Manufacturing and Sales.

Who are Chemcrux Enterprises's main competitors?

Direct peers on record are Aarti Industries, Atul Limited, Navin Fluorine International, Vinati Organics, Tatva Chintan Pharma Chem, Camlin Fine Sciences and Fine Organic Industries. Broad incumbents are SRF Limited and PI Industries. Anupam Rasayan is listed as an emerging player.

Does Chemcrux Enterprises have an API?

No public API is recorded for Chemcrux Enterprises.

What industry is Chemcrux Enterprises in?

Chemcrux Enterprises's product category is Specialty Chemicals (Pharmaceutical Intermediates). Its primary akta.pro industry code is IMAEABAD, Electronic & High-Purity Specialty Chemicals, with a secondary code of IMAEAAAE, Bulk Industrial Solvents. Its NAICS code is 32519 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
ScanXChemcrux Enterprises declares ₹1 per share final dividend for FY26Chemcrux Enterprises declared a ₹1 per share final dividend for FY26 at its 30th AGM on September 17, 2026, approved by shareholders. The 10% payout rate was confirmed, with payment due by October 17, 2026.ScanXChemcrux Enterprises sees exit of two independent directorsChemcrux Enterprises announced that independent directors Bhanubhai Patel and Shailesh Patel ceased their roles on August 23, 2026, following the completion of their second consecutive five-year terms. The company disclosed this leadership change under SEBI listing regulations, citing no material reasons for the departure.ScanXChemcrux Enterprises submits FY26 annual report to BSEChemcrux Enterprises submitted its annual report for the fiscal year ended March 31, 2026, to the Bombay Stock Exchange on August 21, 2026. The submission includes a notice for the 30th Annual General Meeting scheduled for September 17, 2026, where shareholders will vote on a recommended final dividend. The report also highlights strong financial performance in Q1FY27, with standalone net profit rising 135% and consolidated net profit jumping 444% year-on-year.Business StandardChemcrux Enterprises consolidated net profit rises 466.67% in the June 2026 quarterChemcrux Enterprises reported a 466.67% year-over-year increase in consolidated net profit to Rs 0.51 crore for the quarter ended June 2026, up from Rs 0.09 crore in the same quarter of 2025. Revenue grew 32.97% to Rs 21.94 crore during the same period, while operating profit margin improved to 12.26% from 9.88%. The company also showed significant improvements in PBDT (profit before depreciation and taxes) and PBT metrics compared to the prior year period.ScanXChemcrux Enterprises accepts resignation of Sidhdhi Girishkumar Shah as DirectorChemcrux Enterprises Ltd accepted the resignation of Sidhdhi Girishkumar Shah as Non-Executive, Non-Independent Director effective August 4, 2026. She also stepped down as Chairperson of the Stakeholders Relationship Committee, citing pre-occupation as the reason. The Board confirmed there were no other material reasons for the departure.ScanXChemcrux Enterprises appoints Zarna Thakar as independent directorChemcrux Enterprises Ltd appointed Zarna Pankaj Thakar as Additional Independent Director effective August 4, 2026, with a one-year term ending August 3, 2027, subject to shareholder approval at the AGM. Thakar is a Cost and Management Accountant with over 10 years of experience and will receive sitting fees for her role. The appointment follows Chemcrux's strong Q1FY27 performance, where standalone net profit rose 135% to ₹137.43 lakh and revenue grew 31% to ₹2,193.81 lakh.ScanXChemcrux Enterprises net profit rises 135% in Q1FY27Chemcrux Enterprises reported strong Q1FY27 standalone financial results with net profit rising 135% to ₹137.43 lakh and revenue growing 31% to ₹2,193.81 lakh. Consolidated net profit attributable to owners surged 444% to ₹50.52 lakh. The company has scheduled its 30th Annual General Meeting for September 17, 2026.ScanXChemcrux Enterprises' Subsidiary Kalichem Applies for CTE-Amendment to Add Inorganic Chemicals ManufacturingKalichem Private Limited, a wholly-owned subsidiary of Chemcrux Enterprises Limited, has submitted a CTE-Amendment application with the Gujarat Pollution Control Board to add various inorganic chemicals manufacturing at its facility in Vadodara, Gujarat. The application was disclosed to BSE Limited on 14 May 2026 pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015. This move represents Kalichem's proposed diversification into the inorganic chemicals sector, pending regulatory approval from the Gujarat Pollution Control Board.Business StandardChemcrux Enterprises Ltd leads losers in 'B' groupSeveral small-cap stocks on the BSE 'B' group declined on April 17, 2026, with Chemcrux Enterprises Ltd posting the steepest fall at 11.98% to Rs 87.3, followed by Ind-Swift Laboratories Ltd at 9.15% and Mukta Arts Ltd at 7.95%. V R Films & Studios Ltd and Bella Casa Fashion & Retail Ltd also featured among the top losers with declines of 6.25% and 5.78% respectively. Trading volumes for Chemcrux Enterprises Ltd reached 45,219 shares compared to its one-month average daily volume of 15,197 shares.Business StandardLatest Stock Market News, Sensex Today and Nifty Live UpdatesChemcrux Enterprises Ltd has informed BSE that its Board meeting is scheduled for February 5, 2026 to consider and approve the unaudited financial results for the quarter and nine months ended December 31, 2025. The company stated the meeting will also address other related business matters. This is a standard board meeting intimation required for listed companies ahead of quarterly earnings disclosures.